Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: Data from a pan-European survey

Diabetic Medicine

Volumn 24, Issue 4, 2007, Pages 388-391

  Bruckert, E ^a   Baccara Dinet, M ^b   Eschwege, E ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Dohme Chibret Centre de Recherche Riom   (France)

^c INSERM   (France)

Author keywords

Atherosclerosis; Dyslipidaemia; HDL cholesterol; Prevalence; Type 2 diabetes

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL;

ADULT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DYSLIPIDEMIA; EUROPE; FEMALE; HEALTH SURVEY; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW; SEX DIFFERENCE;

EID: 33947407298     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02111.x     Document Type: Review

References (22)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Smith S, Allen J, Blair S, Bonow R, Brass L, Fonarow G et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 2363-2372.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S78.
4. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-52.
5. Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 2006; 29: 32-37.
6. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496-1504.
7. Patel JV, Kirby M, Hughes EA. The Lipid Audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004; 11: 214-217.
8. Romon I, Fosse S, Weill A, Varroud-Vial M, Fagot-Campagna A. Prévalence des complications macrovasculaires et niveau de risque vasculaire des diabétiques en France. Entred 2001. BEH 2001; 12-13: 46-48.
9. Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the 'good' still count? Atherosclerosis 2005; 180: 217-223.
10. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21 : 1927-1934.
11. Bruckert E, Pamphile R, McCoy F, André P. Prevalence of low HDL-C in a European cohort of dyslipidaemic patients. Eur Heart J 2005; 7: F23-F26.
12. Pyorala K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia 2004; 47: 1257-1265.
13. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
15. Armitage J, Bowman L. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004; 15: 439-446.
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
17. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28: 1151-1157.
18. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
19. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
20. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a Working Group report and update. J Am Coll Cardiol 2004; 43: 717-724.
21. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-1268.
22. American Diabetes Association. Dyslipidaemia management in adults with diabetes. Diabetes Care 2004; 27: S68-71.